Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
they were not PCR, they got inherited to 14 cycles plus, right?
So if you want to just tell us a little bit about what you saw in that trial again, in that setting, I think you mentioned the 53% improvement.
Okay.
So one of the things that, of course, a lot of the issues with several cancers is metastasis to the brain
Here, it wasn't immediately clear whether you had a meaningful, or at least the impact on brain mets was not clear.
Do you think we can have sufficient evidence in later follow-ups to assess a CNS prevention benefit in DBO5?
Okay, so last questions here.
If you have been a patient who has been treated with Enherto in the new adjuvant setting and you did not get a major pathologic response, so you were positive still,
Do you believe that you can move on to the DBO5 regime afterwards?
Of course, these are questions that are really relevant to our modeling for DBO9 and DBO3 too.
But let's just consider this question first.
Is four cycles enough from what you know about in HER2 to give you resistance?
Or could it simply be that the patients had, you know, biology just trumped things?
I don't know whatever that means, but you know.
And just to add, there is no known mechanism by which
the ADC is excluded from the tumor.
So you gave two possible mechanisms, the chemo and the antibody.
Is there ever, have you seen any change in the stromal structure or the structure of the tumor, even in mice, et cetera?
I don't know.
That would suggest that could be a mechanism of resistance.
Showing 761–780 of 906 · page 39 of 46
← Previous
Next →